AlvotechALVO
ALVO
About: Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
Employees: 999
0
Funds holding %
of 7,390 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
260% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 5
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
41% more funds holding
Funds holding: 32 [Q3] → 45 (+13) [Q4]
12% more capital invested
Capital invested by funds: $178M [Q3] → $200M (+$21.4M) [Q4]
0.07% more ownership
Funds ownership: 5.03% [Q3] → 5.11% (+0.07%) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q3] → 3 (+0) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$18
88%
upside
Avg. target
$18
88%
upside
High target
$18
88%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
UBS | 88%upside $18 | Buy Initiated | 14 Feb 2025 |
Financial journalist opinion
Based on 13 articles about ALVO published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
This Is a Test From GlobeNewswire
This is a test from GlobeNewswire. Readers are advised to disregard.
Neutral
Seeking Alpha
3 days ago
Alvotech (ALVO) Q4 2024 Earnings Call Transcript
Alvotech (NASDAQ:ALVO ) Q4 2024 Earnings Conference Call March 27, 2025 8:00 AM ET Company Participants Robert Wessman - Chairman, Chief Executive Officer Anil Okay - Chief Commercial Officer Joseph McClellan - Chief Scientific Officer Joel Morales - Chief Financial Officer Benedikt Stefannson - Vice President, Investor Relations Conference Call Participants Ashwani Verma - UBS Operator Good day and thank you for standing by. Welcome to the Alvotech Q4 2024 earnings call.
Neutral
GlobeNewsWire
3 days ago
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.
Neutral
GlobeNewsWire
3 days ago
Alvotech Appoints Dr. Balaji V. Prasad as Chief Strategy Officer
REYKJAVIK, Iceland, March 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the appointment of Dr. Balaji V. Prasad as Chief Strategy Officer.
Neutral
GlobeNewsWire
4 days ago
Alvotech Reports Record Results for 2024 and Provides Business Update
Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on March 27, 2024, at 8:00 am ET (12:00 pm GMT).
Neutral
GlobeNewsWire
4 days ago
Alvotech Reports Record Results for 2024 and Provides Business Update
REYKJAVIK, Iceland, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today reported financial results for full year 2024 and provided a summary of recent pipeline and corporate highlights. Management will conduct a business update conference call and live webcast on March 27, 2024, at 8:00 am ET (12:00 pm GMT).
Neutral
GlobeNewsWire
4 days ago
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
REYKJAVIK, Iceland, PISCATAWAY, N.J. and LONDON, March 26, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair in 2024 were about USD $4.4 billion [1].
Neutral
GlobeNewsWire
4 days ago
UK Medicines and Healthcare Products Regulatory Agency Confirms Acceptance of Marketing Authorization Application for Proposed Biosimilar to Xolair® (omalizumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacturing of biosimilar medicines for patients worldwide, Kashiv Biosciences LLC (“Kashiv”), a fully integrated biopharmaceutical company headquartered in New Jersey, US, and Advanz Pharma, a UK-headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines, today announced that the UK Medicines and Healthcare Products Regulatory Agency (MHRA) has accepted a marketing application for AVT23, a proposed biosimilar to Xolair® (omalizumab), a biologic indicated for treatment of severe persistent allergic asthma and chronic rhinosinusitis with nasal polyps. Global sales of Xolair in 2024 were about USD $4.4 billion [1].
Neutral
GlobeNewsWire
1 week ago
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced the acquisition of Xbrane Biopharma AB's (“Xbrane”) R&D operations and a biosimilar candidate (the “Acquisition”), further expanding Alvotech's development capabilities, and establishing a footprint in the Swedish life science sector. The Acquisition includes Xbrane's R&D operations based in Campus Solna, at the Karolinska Institute outside Stockholm, Sweden, as well as the biosimilar candidate XB003, referencing Cimzia® (certolizumab pegol). Xbrane retains other pre-clinical assets and will focus on the commercialization of this portfolio. Alvotech also announced that it intends to explore the possibility of a listing of Swedish Depository Receipts (SDR), equity share equivalents, on Nasdaq Stockholm, in the future.
Neutral
GlobeNewsWire
1 week ago
Alvotech Acquires Xbrane's R&D Operations in Sweden and Further Affirms its Global Leadership Position in Biosimilars Development and Production
Alvotech acquires all Xbrane's operations and Cimizia biosimilar candidate, further expanding development capabilities, considers listing on Swedish market
Charts implemented using Lightweight Charts™